89bio Inc (NAS:ETNB)

$ 8.855 0.385 (4.55%) Market Cap: 937.83 Mil Enterprise Value: 433.80 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 36/100

89Bio Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023
89Bio Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
89Bio Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
89Bio Inc Topline Results from Phase 2b ENLIVEN Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis - Corporate Call Transcript
Mar 22, 2023
89Bio Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
89Bio Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
89Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
89Bio Inc at Bank of America Healthcare Conference Transcript
May 10, 2022

89Bio Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 08:20PM GMT

Release Date Price: $2.33 (+11.48%)

Transcript 10-Q8-K

Jason Zemansky

Bank of America Merrill Lynch - Analyst

My name is Jason Zemansky. I'm one of the analysts in the healthcare sector of Bank of America. It gives me really great pleasure to introduce Rohan Palekar, CEO of 89bio. He's going to give a presentation. But if there are questions at the end, [we'll] be certainly happy to answer them.

Rohan Palekar

89bio, Inc. - CEO

Great. Thanks, Jason, and thanks for having us at this meeting. Here's our forward-looking statements. For those new to the story, 89bio is a company focused on liver and cardio-metabolic disorders.

A lead program, which we call pegozafermin, it is an FGF21 analog, which is a unique and differentiated FGF21 and we believe has the potential to have a significant impact in these disease states. We've shown really good efficacy data in our 1b/2a studies -- a nice safety and tolerability profile. And using our unique proprietary technology, we have -- able to dose this molecule once a week or once every two weeks.

We're developing the molecule for two very large indications

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.